TICKERNERD
Menu
KYMRKYMRHealthcare · Biotechnology

KYMR Stock Forecast: Kymera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$115
−1.74% on the day

The 23 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $135 — +17.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$9.5B
Ticker Nerd rank
73 / 100
Median analyst target
$135
Analysts covering
23
Revenue$65.0M+466.4% y/y
Operating income−$75.6M
Net income−$61.2M
Free cash flow−$54.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.0%
1M
+4.9%
YTD
+47.7%
1Y
+148.8%
From 52W high
−9.7%
From 52W low
+148.8%
$46
$127
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KYMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
83
Quality
81
Growth
80
Revisions
58
Volatility
53
Issuance
45
Accruals
33
Size
16

Momentum (96): The shares have been drifting up relative to others.

Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KYMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26KYMRHigh $180Median $135Low $111

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
21 Buy2 Hold0 Sell
Low $111Median $135High $180

The green dot is the last close — the median target sits +17.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026Wolfe ResearchUpgradeOutperform—
31 Aug 2026GuggenheimMaintainsBuy$135 → $170
27 Aug 2026Wells FargoMaintainsOverweight$116 → $151
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$133 → $139
30 July 2026Deutsche BankInitiatesHold—
30 July 2026Deutsche BankInitiatesHold$120
28 July 2026GuggenheimMaintainsBuy—
28 July 2026GuggenheimMaintainsBuy$125 → $135
16 July 2026MizuhoMaintainsOutperform—
16 July 2026MizuhoMaintainsOutperform$120 → $140
13 July 2026RBC CapitalDowngradeSector Perform$106 → $115
13 July 2026RBC CapitalDowngradeSector Perform—
30 June 2026B of A SecuritiesMaintainsBuy—
29 June 2026B. Riley SecuritiesMaintainsBuy—
29 June 2026Truist SecuritiesMaintainsBuy—
26 June 2026Canaccord GenuityMaintainsBuy—
25 June 2026BTIGReiteratesBuy—
6 May 2026Canaccord GenuityInitiatesBuy—
16 Mar 2026JefferiesAssumesBuy$122 → $110

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KYMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Kymera Therapeutics, Inc. returned +148.8% against +17.5% for the S&P 500, dividends included.

KYMR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26KYMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KYMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
11
Fundamentals

Kymera Therapeutics, Inc. (KYMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−31.2×

Cheaper than 97% of US stocks

Price / sales
90.1×

Cheaper than 4% of US stocks

Price / book
6.3×

Cheaper than 16% of US stocks

EV / EBITDA
−26.3×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
466.4%

Higher than 98% of US stocks

Earnings growth (YoY)
466.4%

Higher than 95% of US stocks

Gross margin
—
Operating margin
−116.3%

Higher than 13% of US stocks

Net margin
−285.3%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−24.2%

Higher than 30% of US stocks

Return on assets
−15.6%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kymera Therapeutics, Inc. (KYMR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kymera Therapeutics, Inc. has a market value of $9.5B and an enterprise value of $8.9B.

  • Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 466.4% year on year.

  • Net income over the same four quarters: −$299.6M, a −285.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.24.

  • Free cash flow in the twelve months to 30 June 2026: −$238.0M.

  • Shares outstanding: 82.8M.

  • Trailing P/E: −31.2×; forward P/E: −23.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kymera Therapeutics, Inc. employs 273 people — $385K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KYMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYMRKymera Therapeutics, Inc.$9.5B
73
PTGXProtagonist Therapeutics, Inc.$9.5B
97
PRAXPraxis Precision Medicines, Inc.$9.2B
42
IONSIonis Pharmaceuticals, Inc.$9.0B
46
APGEApogee Therapeutics, Inc.$10.2B
—
CYTKCytokinetics, Inc.$10.3B
51
KRYSKrystal Biotech, Inc.$10.3B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KYMR news & analysis

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Kymera Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The company's remarks at the event are now publicly available.

Why it matters — A KYMR watcher would care because the transcript offers insight into the company's latest updates and messaging shared directly with investors at a major industry conference.

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 4 Sept 2026positive

Kymera Therapeutics reported earnings 30 days ago, and its stock has risen 10.2% since that report. The item examines what may be next for the company's shares following this post-earnings gain.

Why it matters — Kymera watchers would care because the article assesses the stock's momentum and outlook following its most recent earnings report.

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

Zacks Investment Research · 3 Sept 2026positive

Kymera Therapeutics is advancing its candidate KT-621 in atopic dermatitis and asthma, with earlier-than-expected atopic dermatitis data reported and potential phase III plans targeted for mid-2027.

Why it matters — Progress on KT-621, including earlier-than-expected data and a clear path toward phase III, is central to Kymera's pipeline outlook.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Kymera Therapeutics announced it will participate in fireside chats and presentations at upcoming investor conferences in September, including the Wells Fargo 21st Annual Healthcare Conference on September 9 and the Citi 2026 Biopharma Back to School Summit on September 10.

Why it matters — The scheduled appearances give Kymera leadership added opportunities to present its clinical-stage oral small molecule degrader platform to investors.

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewsWire · 1 Sept 2026positive

Kymera Therapeutics announced it will present two posters on KT-621, its first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology congresses. The presentations will feature previously reported data from the BroADen Phase 1b trial in moderate to severe atopic dermatitis. The company also noted enrollment is complete in the BROADEN2 Phase 2b AD trial, with topline data expected by late 2026, Phase 3 AD trials planned for mid-2027, and topline data from the BREADTH Phase 2b asthma trial expected in late 2027.

Why it matters — The presentations and advance of KT-621 toward Phase 3 in atopic dermatitis and a Phase 2b asthma trial signal meaningful pipeline progress for Kymera's lead oral STAT6 degrader candidate.

FAQ

Frequently asked questions about KYMR stock

What is the KYMR stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $135, with estimates ranging from $111 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYMR stock a buy right now?

Of the 23 analysts covering Kymera Therapeutics, Inc., 21 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYMR?

As at 12 Sept 2026, Kymera Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will KYMR stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +17.0% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 73 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYMR stock forecast for 2030?

No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $111 to $180 over the next 12 months.

How has KYMR stock performed over the past year?

Kymera Therapeutics, Inc. returned +148.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kymera Therapeutics, Inc. do?

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins.

What is the latest news on KYMR?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Kymera Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The company's remarks at the event are now publicly available.

Company

About Kymera Therapeutics, Inc.

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.

CEO Dr. Nello Mainolfi M.D., Ph.D. · 273 employees · United States · https://www.kymeratx.com